Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05374824 · ClinicalTrials.gov registry record

Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome

A clinical trial of Lennox Gastaut Syndrome, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

Recruiting
Registry status
4,680
Enrollment target
4
Study locations

NCT05374824: Recruiting study of Lennox Gastaut Syndrome, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

NCT05374824 is a study of Lennox Gastaut Syndrome that is actively recruiting participants, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 4,680 participants, above the 139-participant average among 10 other Lennox Gastaut Syndrome trials with a reported enrollment target (3267% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05374824, a study of Lennox Gastaut Syndrome, is actively recruiting participants, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

RECRUITING
Registry status
4,680 participants
Enrollment target
4
Study locations

Study Summary

Lennox-Gastaut syndrome is a serious and rare form of epilepsy that begins in infancy and early childhood. Seizures and their consequences need medical attention, emergency encounters, and hospitalizations. Seizures disrupt home life for the patient and for family. Lennox-Gastaut syndrome is typically accompanied by disabilities in motor, communication, eating, and other skills needed for daily function. Lennox-Gastaut syndrome (LGS) has no cure. Although current treatments may help reduce the number of seizures, none are expected to eliminate them entirely; these treatments are palliative. The main treatments include anti-seizure medications and some surgical approaches, including the implantation of a vagus nerve stimulator (a pacemaker-like generator implanted in the chest wall and programmed by a physician to stimulate the vagus nerve in the neck) and corpus callosotomy (cutting through the band of fibers that connect the two sides of the brain). While both types of treatment (medications and surgeries) produce some benefit by reducing how often the seizures occur, both also have some risks. All medications can, in some patients, produce moderate to severe side effects. This is true of anti-seizure medications. Most patients with LGS take several anti-seizure medications at a time. Surgeries can also have associated risks and is additionally stressful for parents and family members. Currently, there is no strong evidence to support parents and physicians in deciding which type of treatment (more medicines or surgery) will be most successful for a child with LGS, and whether one or the other approach may lessen the toll that seizures take on a child's development and ability to function. This study has two components. It will engage a network of seven pediatric hospitals in the United States where children with Lennox-Gastaut syndrome are cared for and determine whether seizure-related emergency department visits and hospitalizations are more likely to be reduc

Primary Outcome

Emergency health-care utilization for Aim 1a will be defined as the frequency per year of seizure-related emergency department visits and separately seizure-related inpatient admissions in the two years postintervention (surgery or medical), with adjustment for the rate during the year prior to intervention.

Conditions Studied

Study Locations (4)

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago

Michigan

  • C.S. Mott Children's Hospital - Ann Arbor

Missouri

  • St. Louis Children's Hospital - St Louis

Ohio

  • Nationwide Children's - Columbus

Trial Details

FieldValue
Enrollment Target 4,680 participants
Start Date 2022-04-01
Est. Completion 2025-08-31

What NCT05374824 shows while recruiting

NCT05374824 is an observational study that tracks outcomes without assigning an intervention. Its 4,680 participants enrollment target places it among the larger protocols in the corpus, above the 139-participant average among 10 other Lennox Gastaut Syndrome trials with a reported enrollment target (3267% higher).

The record links to 1 condition, with Lennox Gastaut Syndrome appearing as the primary indexed condition, and to 0 interventions.

NCT05374824 reports a single indexed study location in Illinois, Michigan, Missouri.

Frequently Asked Questions

What is clinical trial NCT05374824 about?

NCT05374824 is a clinical study titled "Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome". Lennox-Gastaut syndrome is a serious and rare form of epilepsy that begins in infancy and early childhood. Seizures and their consequences need medical attention, emergency encounters, and hospitalizations. Seizures disrupt home life for the patient and for family. Lennox-Gastaut syndrome is typical...

What is the current status of trial NCT05374824?

This trial is currently recruiting. The enrollment target is 4,680 participants. The study started on 2022-04-01. Estimated completion is 2025-08-31.

What conditions does trial NCT05374824 study?

This clinical trial studies the following conditions: Lennox Gastaut Syndrome.

Who is sponsoring clinical trial NCT05374824?

This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05374824 being conducted?

This trial has 4 study locations across Illinois, Michigan, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lennox Gastaut Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05374824's enrollment target sits among peer trials

4,680 1st of 10 higher than 10 of 10 other Lennox Gastaut Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lennox Gastaut Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04371900 · 4,700 participants · NA

    Michigan Contraceptive Access, Research, and Evaluation Study Children: Phase 1

  • NCT05486572 · 4,700 participants · NA

    Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI

  • NCT06888388 · 4,700 participants

    Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer

  • NCT06535139 · 4,630 participants · NA

    ReMARK: Addressing Disparities in Rural HPV-related Cancer Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05374824, the US trial registry maintained by the National Library of Medicine. NCT05374824 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.